Objectives: The aim of the study is to investigate the predictive value of ischemia-modified albumin (IMA) as an oxidative stress indicator in renal ischemia-reperfusion (I/R) injury. Methods: Forty female Wistar Albino rats were divided into 5 groups: Group-1, sham; group-2, 20 min I/R, group-3, 30 min I/R; group-4, 40 min I/R; and group-5, 60 min I/R. Blood samples were taken, and nephrectomy was performed in the sham group before ischemia was induced. At the end of the defined periods for each group, reperfusion was achieved and a blood sample was taken and nephrectomy was performed. At the end of the 6-hour reperfusion period, the blood sample was taken again and the other kidney is removed. IMA in serum and total anti-oxidant status (TAS), total oxidant status (TOS), and oxidative stress index in both serum and tissue were examined. Results: Serum IMA values were significantly different between the groups (p = 0.009), and there was a significantly difference in TOS values between ischemic serum (p = 0.024) and tissue samples (p = 0.02). However, there was no significant difference in serum and tissue TAS values after ischemia (p = 0.9). Serum IMA, TOS and TAS and tissue TOS and TAS values after reperfusion were not significantly different. There was a significant correlation between tubular damage and ischemia duration in histopathological examination of renal tissue after I/R (p < 0.0001). Conclusion: Serum IMA values increased in parallel with the duration of ischemia, and this increase was supported by histopathological damage findings.

Keywords:
Ischemia reperfusion, Ischemia-modified albumin, Total anti-oxidant status, Total oxidant status
1.
Karaguzel E, Kadihasanoglu M, Kutlu O. Mechanisms of testicular torsion and potential protective agents.
Nat Rev Urol
. 2014 Jul;11(7):391–9.
2.
Halliwell B. Reactive oxygen species in living systems: source, biochemistry, and role in human disease.
Am J Med
. 1991 Sep;91(3C):14S–22S.
3.
Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis.
Physiol Rev
. 2004 Oct;84(4):1381–478.
4.
Tarpey MM, Wink DA, Grisham MB. Methods for detection of reactive metabolites of oxygen and nitrogen: in vitro and in vivo considerations.
Am J Physiol Regul Integr Comp Physiol
. 2004 Mar;286(3):R431–44.
5.
Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation.
Clin Biochem
. 2004 Apr;37(4):277–85.
6.
Erel O. A new automated colorimetric method for measuring total oxidant status.
Clin Biochem
. 2005 Dec;38(12):1103–11.
7.
Talwalkar SS, Bon Homme M, Miller JJ, Elin RJ. Ischemia modified albumin, a marker of acute ischemic events: a pilot study.
Ann Clin Lab Sci
. 2008;38(2):132–7.
8.
Lippi G, Montagnana M, Guidi GC. Albumin cobalt binding and ischemia modified albumin generation: an endogenous response to ischemia?
Int J Cardiol
. 2006 Apr;108(3):410–1.
9.
Turedi S, Gunduz A, Mentese A, Karahan SC, Yilmaz SE, Eroglu O, et al. Value of ischemia-modified albumin in the diagnosis of pulmonary embolism.
Am J Emerg Med
. 2007 Sep;25(7):770–3.
10.
Nath KA, Norby SM. Reactive oxygen species and acute renal failure.
Am J Med
. 2000 Dec;109(8):665–78.
11.
Mouton R, Holder K. Laboratory tests of renal function.
Anaesth Intensive Care Med
. 2006;7(7):240–3.
12.
Becker F, Van Poppel H, Hakenberg OW, Stief C, Gill I, Guazzoni G, et al. Assessing the impact of ischaemia time during partial nephrectomy.
Eur Urol
. 2009 Oct;56(4):625–34.
13.
Bar-Or D, Winkler JV, Vanbenthuysen K, Harris L, Lau E, Hetzel FW. Reduced albumin-cobalt binding with transient myocardial ischemia after elective percutaneous transluminal coronary angioplasty: a preliminary comparison to creatine kinase-MB, myoglobin, and troponin I.
Am Heart J
. 2001 Jun;141(6):985–91.
14.
Bhagavan NV, Lai EM, Rios PA, Yang J, Ortega-Lopez AM, Shinoda H, et al. Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction.
Clin Chem
. 2003 Apr;49(4):581–5.
15.
Wu AH. The ischemia-modified albumin biomarker for myocardial ischemia.
MLO Med Lab Obs
. 2003 Jun;35(6):36–8, 40.
16.
Dundar ZD, Cander B, Gul M, Karabulut KU, Girisgin S. Serum ischemia-modified albumin levels in an experimental acute mesenteric ischemia model.
Acad Emerg Med
. 2010 Nov;17(11):1233–8.
17.
Kutlu O, Mentese A, Turkmen S, Turedi S, Gunduz A, Yulug E, et al. Investigation of the possibility of using ischemia-modified albumin in testicular torsion: an experimental study.
Fertil Steril
. 2011 Mar;95(4):1333–7.
18.
Kiyici A, Mehmetoğlu I, Karaoğlan H, Atalay H, Solak Y, Türk S. Ischemia-modified albumin levels in patients with end-stage renal disease patients on hemodialysis: does albumin analysis method affect albumin-adjusted ischemia-modified albumin levels?
J Clin Lab Anal
. 2010;24(4):273–7.
19.
Kocan H, Citgez S, Yucetas U, Yucetas E, Yazici M, Amasyali AS, et al. Can ischemia-modified albumin be used as an objective biomarker for renal ischemic damage? An experimental study with Wistar albino rats.
Transplant Proc
. 2014 Dec;46(10):3326–9.
20.
Amasyali AS, Akkurt A, Kazan E, Yilmaz M, Erol B, Yildiz Y, et al. The protective effect of tadalafil on IMA (ischemia modified albumin) levels in experimental renal ischemia-reperfusion injury.
Int J Clin Exp Med
. 2015 Sep;8(9):15766–72.
21.
Koksal M, Oğuz E, Baba F, Eren MA, Ciftci H, Demir ME, et al. Effects of melatonin on testis histology, oxidative stress and spermatogenesis after experimental testis ischemia-reperfusion in rats.
Eur Rev Med Pharmacol Sci
. 2012 May;16(5):582–8.
22.
Gökçe A, Oktar S, Koc A, Gonenci R, Yalcinkaya F, Yonden Z, et al. Protective effect of thymoquinone in experimental testicular torsion.
Urol Int
. 2010;85(4):461–5.
23.
Bozkurt Y, Firat U, Atar M, Sancaktutar AA, Pembegul N, Soylemez H, et al. The Protective Effect of Ellagic Acid Against Renal Ischemia-Reperfusion Injury in Male Rats.
Kafkas Univ Vet Fak Derg
. 2012;18(5):823–8.
24.
Tabibi A, Nouralizadeh A, Parvin M, Ghoraishian M, Sadeghi P, Nafar M. An established rat model of inducing reversible acute tubular necrosis.
Iran J Kidney Dis
. 2007 Jul;1(1):16–20.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.